Clinical trials: Mixed Dyslipidaemia
- Condition Mixed Dyslipidaemia
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Hypercholesterolaemia, Mixed Dyslipidaemia
Single Dose Oral Bioequivalence Study of Bempedoic Acid 180 mg Film Coated Tablet and Nilemdo® (Bempedoic Acid) 180 mg Film-coated Tablets in Healthy Adult Human Subjects Under Fasting Conditions.
Single dose oral bioequivalence study of Bempedoic Acid 180 mg Film Coated Tablet and Nilemdo® (Bempedoic Acid) 180 mg Film-coated tablets in healthy adult human subjects under fasting conditions.
- Conditions
- Hypercholesterolaemia, Mixed Dyslipidaemia, Cardiovascular Diseases
- Trial name
- NCT06923956
- Testing
- Bempedoic Acid Film Coated Tablet, Nilemdo® (Bempedoic Acid) Film-coated tablets
- Where
- India
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Humanis Saglık Anonim Sirketi
Mixed Dyslipidemia, Food Effect Study of AD-117
A Study to Evaluate the Effect of Food on the Pharmacokinetic Characteristics and Safety Profile of AD-117 in Healthy Adult Volunteers
A Study to Evaluate the Effect of Food on the Pharmacokinetic Characteristics and Safety Profile of AD-117 in Healthy Adult Volunteers
- Trial name
- NCT07495514
- Testing
- AD-117
- Where
- South Korea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Addpharma Inc.
Primary Hyperlipidemia and Mixed Dyslipidemia
Effects on Lipoprotein Metabolism From PCSK9 Inhibition Utilizing a Monoclonal Antibody
This is a randomized, double-blind, placebo-controlled trial to evaluate the effect of evolocumab, atorvastatin, and combination therapy on lipoprotein kinetics.
- Trial name
- FLOREY (NCT02189837)
- Testing
- Evolocumab, Atorvastatin
- Where
- 2 sites in Australia
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Amgen
Mixed Dyslipidemia
A Study to Compare to PK Characteristics and Safety Profiles Between PA-111 and PA-111A
Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of PA-111 in healthy subjects.
- Trial name
- NCT06932705
- Testing
- PA-111, PA-111A
- Where
- South Korea
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Addpharma Inc.
Hyperlipemia, Mixed
Study to Evaluate the Safety and PK of UI018
This Study is to evaluate the safety and pharmacokinetics of a fixed dose combination formulation and co-administration.
- Trial name
- NCT05085184
- Testing
- administration of UI018, co-administration of UIC201806 and UIC201602
- Where
- South Korea
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Korea United Pharm. Inc.
Mixed Dyslipidemia
Clinical Trial to Evaluate the Safety, Pharmacokinetic Characteristics of DW5124 and DW5124-R, and the Effect of Food on DW5124 in Healthy Adult Volunteers
This study aimed to evaluate the safety and pharmacokinetic characteristics of DW5124 and DW5124-R, and the effect of food on DW5124, in healthy adult volunteers.
- Trial name
- NCT07319559
- Testing
- DW5124, DW5124-R
- Where
- South Korea
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Daewon Pharmaceutical Co., Ltd.
Mixed Dyslipidemia
The Food Effect on PK Characteristics and Safety Profiles of PA-111
Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of PA-111 in healthy subjects.
- Trial name
- NCT06976489
- Testing
- PA-111
- Where
- South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Addpharma Inc.
Mixed Dyslipidemia
A Study to Compare to PK Characteristics and Safety Profiles Between AD-117 and AD-117A
Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of AD-117 in healthy subjects.
- Trial name
- NCT07152873
- Testing
- AD-117, AD-117A
- Where
- South Korea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Addpharma Inc.